Analysts Slash enGene Price Targets 40% After ENG-1 Trial Misses Endpoints
Three Wall Street analysts downgraded enGene Therapeutics shares after interim data from its Phase Ib/II ENG-1 trial failed to reach primary efficacy and safety endpoints, prompting average price-target cuts of 40% to a $5–$7 range. Jefferies, SVB Leerink and RBC each shifted ratings from Buy to Hold.
1. Analyst Downgrades Follow Disappointing ENG-1 Data
enGene Therapeutics saw its stock ratings reduced after interim data from its Phase Ib/II ENG-1 trial in solid tumors failed to meet both primary efficacy and safety benchmarks. Jefferies cut its recommendation from Buy to Hold and lowered its price target to $6 from $12, while SVB Leerink and RBC trimmed targets to $5 and $7 respectively. The downgrades reflect investor concern over slower clinical progress and potential cash-burn implications for funding future trials.